

2015
Press release



www.genfit.com

GENFIT: ORDINARY GENERAL SHAREHOLDERS' MEETING OF JUNE 3, 2015 – AVAILABILITY OF PREPARATORY DOCUMENTS

Lille (France), Boston (Massachusetts, United States), May 7th, 2015 – GENFIT (Euronext: GNFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in metabolic and inflammatory diseases, that notably affect the liver or the gastrointestinal system, today announces the availability of preparatory documents for the Ordinary General Shareholders' Meeting ("the Shareholders' Meeting") to be held on June 3rd, 2015, at 10:30am, in the Faculty of Pharmaceutical & Biological Sciences of Lille premises, located Parc Eurasanté, 3 rue du Professeur Laguesse, F-59000 Lille.

The Notice of Meeting comprising the agenda and the draft resolution was published in the French official legal bulletin ("BALO") of April 29th, 2015. It is also available on the Company's website, in the investors' room (<http://www.genfit.com/investors/documentation-center/>).

All documentation regarding this Shareholders' Meeting is available to shareholders in accordance with existing regulations, and is available on the Company's website, in the investors' room (<http://www.genfit.com/investors/documentation-center/>).

Documents listed in Article R.225-83 of the French Commercial Code are available to shareholders in accordance with existing regulations.

Any shareholder holding registered shares may, up to the fifth day, inclusive, prior to the Shareholders' Meeting, request these documents from the Company. For shareholders holding bearer shares, the exercise of this right is subject to the submission of a shareholding certificate delivered by their financial intermediary.

Any shareholder may consult these documents at the registered office of the Company during 15 days preceding the Shareholders' Meeting.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide. GENFIT's R&D efforts are focused on contributing to bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as the inflammatory bowel disease). GENFIT implements mutually beneficial approaches that combine novel treatments and biomarkers; its research programs have resulted in the creation of a rich and diversified pipeline of drug candidates, including GENFIT's lead proprietary compound, GFT505, that has completed a positive Phase 2b in NASH and is currently launching a Phase 3 study.

With facilities in Lille, France, and Boston, MA (USA), the Company has approximately 90 employees. GENFIT is a public company listed in compartment B of Euronext's regulated market in Paris (Euronext: GNFT; ISIN: FR0004163111). www.genfit.com

Disclaimer:

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on GENFIT's website (www.genfit.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in GENFIT in any country.

Contacts

GENFIT | Jean-François Mouney - CEO & Chairman of the Management Board | Ph. +333 2016 4000

MILESTONES – Relation Presse | Bruno Arabian | Ph. +331 8362 3484 / +336 8788 4726 – barabian@milestones.fr